{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T07:51:13Z","timestamp":1772524273403,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1124\/dmd.117.076851","type":"journal-article","created":{"date-parts":[[2017,9,15]],"date-time":"2017-09-15T00:30:19Z","timestamp":1505435419000},"page":"1304-1316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Physiologically Based Pharmacokinetic Model Predictions of Panobinostat (LBH589) as a Victim and Perpetrator of Drug-Drug Interactions"],"prefix":"10.1016","volume":"45","author":[{"given":"Heidi J.","family":"Einolf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina S.","family":"Won","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dung Y.","family":"Chun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Handan","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James B.","family":"Mangold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.117.076851_bib1","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.115.066845","article-title":"Prediction of drug-drug interactions arising from CYP3A induction using a physiologically based dynamic model","volume":"44","author":"Almond","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.076851_bib2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1358\/dot.2015.51.8.2362311","article-title":"Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma","volume":"51","author":"Cheng","year":"2015","journal-title":"Drugs Today (Barc)"},{"key":"10.1124\/dmd.117.076851_bib3","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00280-012-1940-9","article-title":"Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients","volume":"70","author":"Clive","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.117.076851_bib4","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1038\/leu.2013.38","article-title":"Phase Ia\/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies","volume":"27","author":"DeAngelo","year":"2013","journal-title":"Leukemia"},{"key":"10.1124\/dmd.117.076851_bib5","first-page":"1257","article-title":"Comparison of different approaches to predict metabolic drug-drug interactions","volume":"37","author":"Einolf","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.117.076851_bib6","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s00280-013-2237-3","article-title":"A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer","volume":"72","author":"Feld","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.117.076851_bib7","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3109\/00498254.2015.1014944","article-title":"Disposition and metabolism of [(14)C] Sacubitril\/Valsartan (formerly LCZ696) an angiotensin receptor neprilysin inhibitor, in healthy subjects","volume":"46","author":"Flarakos","year":"2016","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.117.076851_bib8","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1021\/jm900648x","article-title":"Hydroxamates: relationships between structure and plasma stability","volume":"52","author":"Flipo","year":"2009","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.117.076851_bib10","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s40265-015-0388-8","article-title":"Panobinostat: first global approval","volume":"75","author":"Garnock-Jones","year":"2015","journal-title":"Drugs"},{"key":"10.1124\/dmd.117.076851_bib11","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1124\/dmd.110.036103","article-title":"Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions","volume":"39","author":"Guest","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.076851_bib12","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00280-011-1693-x","article-title":"Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor","volume":"68","author":"Hamberg","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.117.076851_bib13","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1002\/jps.23570","article-title":"The utility of modeling and simulation in drug development and regulatory review","volume":"102","author":"Huang","year":"2013","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.117.076851_bib14","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/clpt.2011.320","article-title":"The role of physiologically based pharmacokinetic modeling in regulatory review","volume":"91","author":"Huang","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.117.076851_bib15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s40495-016-0059-9","article-title":"Recent advances in development and application of Physiologically-Based Pharmacokinetic (PBPK) models: a transition from academic curiosity to regulatory acceptance","volume":"2","author":"Jamei","year":"2016","journal-title":"Curr Pharmacol Rep"},{"key":"10.1124\/dmd.117.076851_bib16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/cpt.37","article-title":"Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective","volume":"97","author":"Jones","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.117.076851_bib17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00228-015-1967-z","article-title":"Panobinostat PK\/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed\/refractory multiple myeloma","volume":"72","author":"Mu","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.117.076851_bib18","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/dmd.106.012633","article-title":"Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions","volume":"35","author":"Obach","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.076851_bib19","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1208\/s12248-016-9957-3","article-title":"Physiologically based absorption modeling to explore the impact of food and gastric pH changes on the pharmacokinetics of alectinib","volume":"18","author":"Parrott","year":"2016","journal-title":"AAPS J"},{"key":"10.1124\/dmd.117.076851_bib20","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3109\/00365529709011199","article-title":"A double-blind placebo-controlled study on the effects of omeprazole on gut hormone secretion and gastric emptying rate","volume":"32","author":"Rasmussen","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"10.1124\/dmd.117.076851_bib21","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1053\/jhep.2002.33215","article-title":"The effects of portal shunts on intestinal cytochrome P450 3A activity","volume":"35","author":"Rostami-Hodjegan","year":"2002","journal-title":"Hepatology"},{"key":"10.1124\/dmd.117.076851_bib22","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1124\/dmd.115.065920","article-title":"Physiologically based Pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification","volume":"43","author":"Sager","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.076851_bib23","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1200\/JCO.2012.46.7068","article-title":"Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma","volume":"31","author":"San-Miguel","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.117.076851_bib24","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00228-015-1846-7","article-title":"Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors","volume":"71","author":"Savelieva","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.117.076851_bib25","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00280-011-1758-x","article-title":"The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer","volume":"69","author":"Shapiro","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.117.076851_bib26","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1124\/dmd.108.020602","article-title":"Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction","volume":"36","author":"Shou","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.076851_bib27","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40262-015-0330-y","article-title":"Predicting the effect of CYP3A inducers on the pharmacokinetics of substrate drugs using physiologically based pharmacokinetic (PBPK) modeling: An analysis of PBPK submissions to the US FDA","volume":"55","author":"Wagner","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.117.076851_bib29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/clpt.2012.68","article-title":"Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions","volume":"92","author":"Zhao","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.117.076851_bib30","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/clpt.2010.298","article-title":"Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review","volume":"89","author":"Zhao","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.117.076851_bib31","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1208\/s12248-016-9972-4","article-title":"Utilizing in vitro dissolution-permeation chamber for the quantitative prediction of pH-dependent drug-drug interactions with acid-reducing agents: a comparison with physiologically based pharmacokinetic modeling","volume":"18","author":"Zhu","year":"2016","journal-title":"AAPS J"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624054199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624054199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.117.076851","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:32:15Z","timestamp":1739903535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624054199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0090955624054199"],"URL":"https:\/\/doi.org\/10.1124\/dmd.117.076851","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physiologically Based Pharmacokinetic Model Predictions of Panobinostat (LBH589) as a Victim and Perpetrator of Drug-Drug Interactions","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.117.076851","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}